COST-EFFECTIVENESS COMPARISON OF BOTULINUM TOXIN TYPE A PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN THE TREATMENT OF IDIOPATHIC OVERACTIVE BLADDER WITH URINARY INCONTINENCE AMONG PATIENTS NOT ADEQUATELY MANAGED BY ANTICHOLINERGIC THERAPY IN FRANCE

被引：1

作者：

Ruffion, A. ^{[1
]}

Velard, M. ^{[2
]}

Loveman, C. ^{[3
]}

Khalaf, K. ^{[4
]}

Roze, S. ^{[5
]}

Pignata, M. ^{[5
]}

Stanisic, S. ^{[6
]}

Lister, J. ^{[7
]}

机构：

[1] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[2] Allergan France SAS, Courbevoie, France

[3] Allergan Holdings Ltd, Marlow, Bucks, England

[4] Allergan Pharmaceut Inc, Irvine, CA USA

[5] HEVA HEOR, Lyon, France

[6] LASER Grp, Milan, Italy

[7] LASER ANALYT, Lorrach, Germany

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 07期

关键词：

D O I：

10.1016/j.jval.2014.08.1330

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PUK22

引用

页码：A470 / A470

页数：1

共 50 条

[41] COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY: A FRENCH HEALTHCARE SYSTEM PERSPECTIVE
Cariou, C.
Baba, J.
Gherardi, A.
Roze, S.
Viriato, D.
VALUE IN HEALTH, 2019, 22 : S405 - S405
[42] COST-EFFECTIVENESS ANALYSIS OF ADJUVANT ATEZOLIZUMAB VERSUS BEST SUPPORTIVE CARE IN THE TREATMENT OF PATIENTS WITH RESECTABLE EARLYSTAGE NON -SMALL CELL LUNG CANCER AND PD-L1≥50% EXPRESSION
Escudero, V
Collado, R.
de Castro, J.
Insa, A.
Martinez, A.
Fernandez, E.
Sullivan, I
Flores, A.
Arrabal, N.
Carcedo, D.
Manzaneque, A.
VALUE IN HEALTH, 2022, 25 (12) : S153 - S153
[43] Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
Escudero-Vilaplana, Vicente
Collado-Borrell, Roberto
De Castro, Javier
Insa, Amelia
Martinez, Alex
Fernandez, Elena
Sullivan, Ivana
Flores, Andres
Arrabal, Natalia
Carcedo, David
Manzaneque, Alba
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 445 - 453
[44] COST-EFFECTIVENESS OF PONATINIB FOLLOWED BY STEM CELL TRANSPLANT VERSUS BEST SUPPORTIVE CARE FOR UK PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA AFTER FAILURE OF DASATINIB
Iannazzo, S.
Chiroli, S.
Rowntree, C.
McGarry, L.
Briggs, A.
VALUE IN HEALTH, 2015, 18 (07) : A667 - A668
[45] COST-EFFECTIVENESS OF TREATING METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS WHOSE DISEASE FAILED ON ONE PRIOR VEGF-TKI THERAPY WITH EVEROLIMUS COMPARED TO TREATING WITH BEST SUPPORTIVE CARE (BSC) ALONE IN CANADA
Casciano, R.
Chulikavit, M.
El Ouagari, K.
Wang, X.
VALUE IN HEALTH, 2011, 14 (07) : A445 - A446
[46] Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial (vol 18, pg 672, 2017)
Garcia-Donas, J.
Font, A.
Perez-Valderrama, B.
LANCET ONCOLOGY, 2019, 20 (01): : E9 - E9
[47] The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada
Christopher Hillis
Colin Vicente
Graeme Ball
PharmacoEconomics, 2022, 40 : 917 - 928
[48] The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada
Hillis, Christopher
Vicente, Colin
Ball, Graeme
PHARMACOECONOMICS, 2022, 40 (09) : 917 - 928
[49] COST-EFFECTIVENESS OF TREATING METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS WHOSE DISEASE FAILED ON VEGF-TKI THERAPIES WITH EVEROLIMUS COMPARED TO TREATING WITH BEST SUPPORTIVE CARE (BSC) ALONE: A CANADIAN SOCIETAL PERSPECTIVE
El Ouagari, K.
Chulikavit, M.
ANNALS OF ONCOLOGY, 2010, 21 : 291 - 291
[50] Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis (vol 9, pg e1305, 2021)
Painschab, M. S.
Kohler, R.
Kimani, S.
LANCET GLOBAL HEALTH, 2021, 9 (09): : E1215 - E1215

← 1 2 3 4 5 →